Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal

Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2

Ravn, 1999, Alendronate and estrogen-progestin in the long-term prevention of bone loss, Ann Intern Med, 131, 935, 10.7326/0003-4819-131-12-199912210-00005

Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201

Ravn, 2000, Alendronate in early postmenopausal women, J Clin Endocrinol Metab, 85, 1492, 10.1210/jc.85.4.1492

McClung, 1998, Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group, Ann Intern Med, 128, 253, 10.7326/0003-4819-128-4-199802150-00001

Hosking, 1998, Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group, N Engl J Med, 338, 485, 10.1056/NEJM199802193380801

Christgau, 1998, Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides, Clin Chem, 44, 2290, 10.1093/clinchem/44.11.2290

Rosenquist, 1995, Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies, Clin Chem, 41, 1439, 10.1093/clinchem/41.10.1439

Stock, 1997, Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women, Am J Med, 103, 291, 10.1016/S0002-9343(97)00130-7

Tonino, 2000, Skeletal benefits of alendronate, J Clin Endocrinol Metab, 85, 3109, 10.1210/jc.85.9.3109

Heaney, 1997, Bisphosphonate effects and the bone remodeling transient, J Bone Miner Res, 12, 1143, 10.1359/jbmr.1997.12.8.1143

Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, 1475, 10.1172/JCI119668

Parfitt, 1996, A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates, J Bone Miner Res, 11, 150, 10.1002/jbmr.5650110203

Orr-Walker, 1997, Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis, Clin Endocrinol (Oxf), 46, 87, 10.1046/j.1365-2265.1997.d01-1741.x

McClung, 2002, Resolution of effect following alendronate, J Bone Miner Res, 17, 134

Ravn, 1999, Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study, J Clin Endocrinol Metab, 84, 2363, 10.1210/jc.84.7.2363

Lin, 1996, Bisphosphonates, Bone, 18, 75, 10.1016/8756-3282(95)00445-9

Fleisch, 1997, Bisphosphonates, Ann Med, 29, 55, 10.3109/07853899708998743